Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1379 • ACR Convergence 2022
Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)
Nicholas Gold¹, Fangming Liao¹, JingJing Cao¹, Daniela Dominguez¹, Andrea Knight², Deborah Levy³ and Linda Hiraki⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease capable of affecting multiple organ systems. Genetic variants in the Human Leukocyte Antigen (HLA) are associated…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Amar Kumar¹, Joshua Tartarian², Valentina Shakhnovich³, Carl Langefeld⁴, Daniel Lovell⁵, Susan Thompson⁶, Mara Becker⁷ and Ryan Funk⁸, ¹University of Kansas, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ⁷Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁸University of Kansas, Leawood, KS
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
Abstract Number: 0042 • ACR Convergence 2022
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Amritha Yellamilli¹, Victoria Osinski², Maria Firulyova³, Jennifer Auger⁴, Lee Meier², Jessica Faragher⁵, Aubyn Marath⁶, Konstantin Zaitsev³ and Bryce Binstadt⁵, ¹Stanford University School of Medicine, Palo Alto, ²University of Minnesota School of Medicine, Minneapolis, MN, ³ITMO University, Saint Petersburg, Russia, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵University of Minnesota, Minneapolis, MN, ⁶CardioStart, Portland
Background/Purpose: Valvular carditis is a serious complication of systemic autoimmune diseases. Although endothelial cells are thought to play an important role in autoimmune valvular carditis,…
Abstract Number: 0663 • ACR Convergence 2022
Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Zurong Wan², Preetha Balasubramanian³, Juan Rodriguez Alcazar³, Lynnette Walters⁴, Jeanine Baisch², karen onel⁵, Tracey Wright⁶, Virginia Pascual³ and Simone Caielli³, ¹Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Scottish Rite Hospital for Children, Allen, TX, ⁵Hospital for Special Surgery, New York, NY, ⁶UT Southwestern, Plano, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type 1 interferon signature. It…
Abstract Number: 0879 • ACR Convergence 2022
Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
Angela Zimmer¹, Ariane Klein¹ and Gerd Horneff², ¹Asklepios, St. Augustin, Germany, ²Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany
Background/Purpose: Golimumab (GOL) is approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety and…
Abstract Number: 1361 • ACR Convergence 2022
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Asra Firdous¹, Megan Quinlan-Waters¹, Amy Cassedy², Angela Merritt¹, Hermine Brunner³, Alexei Grom¹, Daniel Lovell¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cleveland, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis and multi-organ involvement. Treatment with systemic immunosuppression…
Abstract Number: 1380 • ACR Convergence 2022
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
Rebecca Sadun¹, Laura Lewandowski², Alexandre Belot³, Eve Smith⁴ and Jennifer Cooper⁵, ¹Duke University, Durham, NC, ²NIAMS, NIH, Bethesda, MD, ³Hospices Civils de Lyon, Collonges au mont d'or, France, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
Abstract Number: 1933 • ACR Convergence 2022
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Roberta DeBiasi², Lauren Arrigoni², Kevin Rubenstein³, Jason Liang⁴, James Bost², Marcin Gierdalski², Max Wolff³, Mallory Barrix², Maureen Edu², Saira Huq², Shera Weyers³, Patricia Bandettini⁵, Dorothy Bulas², Tom Burklow⁶, Marcus Chen⁵, Sanchita Das⁶, Robin Dewar³, Joseph Fontana⁵, Ashraf Harahsheh², Linda Herbert², Anastassios Koumbourlis², Andrew Lipton⁵, Laura Olivieri², Dinesh Pillai², Vandana Sachdev⁵, Craig Sable², Audrey Thurm⁷, Evrim Turkbey⁶, Alexandra Yonts², Jonathan Zember², Eric Vilain², Meghan Delaney², Luigi Notarangelo⁴, David Wessel⁸ and Karyl Barron⁴, ¹NIAID/NIH, Garrett Park, MD, ²Children's National Hospital, Washington, DC, ³Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴NIAID/NIH, Bethesda, MD, ⁵NHLBI/NIH, Bethesda, MD, ⁶CC/NIH, Bethesda, MD, ⁷NIMH/NIH, Bethesda, MD, ⁸Children's National Hospital, Washington, MD
Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
Abstract Number: 2212 • ACR Convergence 2022
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Hermine Brunner¹, Athimalaipet Ramanan², Gerd Horneff³, Kirsten Minden⁴, Inmaculada Calvo Penades⁵, Mauro Zucchetto⁶, Laura Brockwell⁷, Oliver Gordon⁷ and Fabrizio De Benedetti⁸, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Bristol Royal Hospital for Children, Bristol, United Kingdom, ³Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁶Parexel International, Milano, Italy, ⁷Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁸Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Dosing regimens for subcutaneous tocilizumab (SC-TCZ) in patients with polyarticular-course or systemic juvenile idiopathic arthritis (pJIA or sJIA) were determined for SC-TCZ in 2…
Abstract Number: 0043 • ACR Convergence 2022
Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
Jessica Turnier¹, Celine Berthier², Madison McClune², Sarah Vandenbergen², Johann Gudjonsson², Alex Tsoi² and J. Michelle Kahlenberg², ¹University of Michigan, Saline, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) frequently persists even in the absence of active muscle disease. Tape stripping is a non-invasive skin sampling method…
Abstract Number: 0729 • ACR Convergence 2022
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Y. Ingrid Goh¹, Esi Morgan², Meghan Ryan³, Beth Gottlieb⁴ and Nancy Pan⁵, ¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ²Seattle Children's Hospital, Seattle, WA, ³University of Minnesota, Vadnais Heights, MN, ⁴Cohen Children's Medical Center, Lake Success, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Patients/proxies (Pts) complete patient reported outcome measures (PROMs) to inform their healthcare team about their health status. PROMs completed by Pts prior to their…
Abstract Number: 0880 • ACR Convergence 2022
Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy Brandon¹, Amita Aggarwal², Ruben Burgos vargas³, Robert Colbert⁴, Gerd Horneff⁵, Rik Joos⁶, Ronald Laxer⁷, Kirsten Minden⁸, Angelo Ravelli⁹, Nicola Ruperto¹⁰, Judith Smith¹¹, Matthew Stoll¹², Shirley Tse⁷, Filip Van den bosch¹³, Walter P Maksymowych¹⁴, Robert G Lambert¹⁵, David Biko¹⁶, Nancy Chauvin¹⁷, Michael Francavilla¹⁶, Jacob Jaremko¹⁵, Nele Herregods¹⁸, Jennifer Faerber¹, Ozgur Kasapcopur¹⁹, Mehmet YILDIZ²⁰, Alison Hendry²¹ and Pamela Weiss²², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³hospital general de mexico, Ciudad de México, Mexico, ⁴NIH/NIAMS, Bethesda, MD, ⁵Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁶Ghent University Hospital, Basel, Switzerland, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Charité Universitätsmedizin Berlin, Berlin, Germany, ⁹Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁰IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹¹University of Wisconsin, Madison, WI, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁵University of Alberta, Edmonton, AB, Canada, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Penn State Health, Hershey, PA, ¹⁸Ghent University Hospital, Ghent, Belgium, ¹⁹Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ²⁰Istanbul University-Cerrahpaşa, Istanbul, Turkey, ²¹Middlemore Hospital, Auckland, ²²Children's Hospital of Philadelphia, Glen Mills, PA
Background/Purpose: Axial disease in juvenile spondyloarthritis (JSpA) is difficult to assess in children and the role of MRI in rheumatologist diagnosis has not yet been…
Abstract Number: 1362 • ACR Convergence 2022
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
Hanna Kim¹, Didem Saygin², Christian Douglas³, john mcgrath³, Jesse Wilkerson³, angela Pistorio⁴, Ann Reed⁵, Chester Oddis⁶, Frederick Miller⁷, Jiří Vencovský⁸, Nicola Ruperto⁹, Rohit Aggarwal¹⁰ and Lisa G Rider⁷, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ²University of Chicago, Chicago, IL, ³Social and Scientific Systems, Inc., Durham, NC, ⁴IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁵Duke University School of Medicine, Durham, NC, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile dermatomyositis (JDM) ACR-EULAR myositis response criteria (MRC) were developed based on absolute % changes in 6 core set measures (CSM) differentially weighted to…
Abstract Number: 1382 • ACR Convergence 2022
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
Leigh Stubbs¹, Oluwaseun Ogunbona², Adekunle Adesina¹, Sara Anvari¹, Emily Beil¹, Jamie Lai¹, Andrea Ramirez¹, Vibha Szafron¹, Matthew Ditzler¹ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Houston Methodist Hospital, Houston, TX
Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disease. Since described in 1975, less than 30 pediatric cases have been reported. EF presents with painful…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].